首页> 美国卫生研究院文献>Communications Biology >PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

【2h】

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

机译：PD-1衍生的Ca-170是一种口服免疫检查点抑制剂其表现出临床前的抗肿瘤疗效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Evolution of CA-170: profiles of hit and lead compounds.

机译：CA-170的演变：击中和铅化合物的谱。

著录项

期刊名称 Communications Biology
作者
Pottayil G. Sasikumar; Naremaddepalli S. Sudarshan; Srinivas Adurthi; Raghuveer K. Ramachandra; Dodderi S. Samiulla; Anirudha Lakshminarasimhan; Anuradha Ramanathan; Talapaneni Chandrasekhar; Amit A. Dhudashiya; Sumalatha R. Talapati; Nagesh Gowda; Sreenivasulareddy Palakolanu; Jiju Mani; Bandi Srinivasrao; David Joseph; Nigam Kumar; Rashmi Nair; Hanudatta S. Atreya; Nagaraj Gowda; Murali Ramachandra;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 12
原文格式 PDF
正文语种
中图分类生物学;
关键词

机译：小分子;药物发现;

相似文献

外文文献
中文文献
专利

1. The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors [J] . Emanuela Romano, Pedro Romero Journal for ImmunoTherapy of Cancer . 2015,第S1期

机译：破坏癌症中PD-1 / PD-L1免疫检查点的治疗前景：释放CD8 T细胞介导的抗肿瘤活性可在各种实体瘤中产生显着的前所未有的临床疗效
2. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade [J] . Hanna Grauers Wiktorin, Malin S. Nilsson, Roberta Kiffin, Cancer immunology, immunotherapy : . 2019,第2期

机译：组胺靶向霉菌衍生的抑制细胞，提高PD-1 / PD-L1检查点封闭的抗肿瘤效果
3. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors [J] . Satya Das, Douglas B. Johnson Journal for ImmunoTherapy of Cancer . 2019,第1期

机译：免疫检查点抑制剂的免疫相关不良事件和抗肿瘤功效
4. Multiparametric Flow Cytometry Analysis of Checkpoint Inhibitors (PD-1 and PD-L1) in Dissociated Tumor and Normal Tissues [C] . Shawn P. Fahl International Molecular Medicine Tri-Conference. . 2019

机译：离聚肿瘤和正常组织中检查点抑制剂（PD-1和PD-L1）的多次流式细胞术分析
5. Understanding How Adrenergic Stress Signaling Impacts the Anti-Tumor Immune Response and the Efficacy of Checkpoint Inhibitors in Murine Tumor Models [D] . Bucsek, Mark Joseph. 2019

机译：了解肾上腺素能应激信号如何影响抗肿瘤免疫应答以及检查点抑制剂在鼠肿瘤模型中的疗效
6. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade [O] . Hanna Grauers Wiktorin, Malin S. Nilsson, Roberta Kiffin, -1

机译：组胺靶向髓样来源的抑制细胞并提高PD-1 / PD-L1检查点封锁的抗肿瘤功效
7. The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. [O] . Romano, E., Romero, P. 2015

机译：破坏癌症中PD-1 / PD-L1免疫检查点的治疗前景：释放CD8 T细胞介导的抗肿瘤活性可在各种实体瘤中产生显着的前所未有的临床疗效。

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

摘要

著录项

相似文献

相关主题

期刊订阅